Clinical trials: CRC, Colorectal Cancer
Familial Adenomatous Polyposis (FAP)
A Safety Study of ST316 in Participants With Familial Adenomatous Polyposis (FAP).
This is a Phase 1b, open- label, dose-optimization study evaluating ST316 in adult participants with familial adenomatous polyposis (FAP) who have undergone colectomy and have recurrent polyps.
- Trial name
- FAP (NCT07729371)
- Testing
- ST316 IV
- Volunteers
- 40 people
- Sponsor
- Sapience Therapeutics
Pancreatic Ductal Adenocarcinoma, Colorectal Cancer
Study to Assess the Safety and Efficacy of Intravenous Injection of the Imaging Agent 111In-IPN01087 in Patients With Locally Advanced or Metastatic Pancreatic or Colorectal Cancer.
111Indium-labelled IPN01087 (111In-IPN01087) is developed as a radioactive diagnostic imaging agent in patients with colorectal or pancreatic cancer.
- Trial name
- NCT04632199
- Testing
- 111In-IPN01087 Low dose, 111In-IPN01087 High dose
- Where
- 5 sites in Belgium, France
- Sponsor
- Ipsen
Colorectal Adenocarcinoma
A Study to Evaluate the Efficacy of VVD-133214 in Combination With Pembrolizumab Compared With Pembrolizumab Alone in Participants With Advanced Cancer of the Colon or Rectum
Researchers are looking for a better way to treat people with advanced colorectal cancer. Colorectal cancer (cancer of the colon or rectum) is one of the most common cancers worldwide.
- Trial name
- NCT07811193
- Testing
- VVD-133214, Pembrolizumab
- Where
- 122 sites in United States, Argentina and 20 more
- Volunteers
- 140 people
- Sponsor
- Vividion Therapeutics, Inc.
Solid Tumor, Non-Small-Cell Lung Cancer
A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
Genes contain genetic code which tell the body which proteins to make. Many types of cancer are caused by changes, or mutations, in a gene called KRAS.
- Conditions
- Solid Tumor, Non-Small-Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer
- Trial name
- NCT07094204
- Testing
- ASP5834, panitumumab
- Where
- 22 sites in United States, France and 3 more
- Volunteers
- 404 people
- Sponsor
- Astellas Pharma Inc
Colorectal Cancer, Non-Small Cell Lung Cancer
A Study of Avastin in Combination With Chemotherapy for Treatment of Colorectal Cancer and Non-Small Cell Lung Cancer (ARIES)
This is an observational study designed to follow patients with metastatic or locally advanced and unresectable CRC or locally advanced or metastatic NSCLC (excluding predominant squamous histology) who are receiving Avastin in…
- Trial name
- ARIES (NCT00388206)
- Volunteers
- 3,998 people
- Sponsor
- Genentech, Inc.
Metastatic Colorectal Cancer
Sotevtamab (AB-16B5) Combined With FOLFOX as Neoadjuvant Treatment Prior to Resection of Colorectal Cancer Liver Metastasis
This Phase II study will recruit 17 colorectal cancer patients with liver-dominant metastases. All recruited patients will receive Sotevtamab at a dose of 800 mg once weekly for 6 cycles combined with FOLFOX once every 2 weeks…
- Trial name
- EGIA-003 (NCT06225843)
- Testing
- Sotevtamab, FOLFOX
- Where
- Canada
- Volunteers
- 17 people
- Sponsor
- Alethia Biotherapeutics
Colorectal Cancer
Evaluation of MM-151 + Nal-IRI + 5-FU + Leucovorin in RAS/RAF Wild-type Metastatic Colorectal Cancer
A phase 1b/2a study evaluating the combination of MM-151 + nal-IRI + 5-FU + Leucovorin in RAS/RAF wild-type Metastatic Colorectal Cancer.
- Trial name
- NCT02785068
- Testing
- MM-151, nal-IRI, Leucovorin
- Sponsor
- Merrimack Pharmaceuticals
Metastatic Colorectal Carcinoma
A Study Of PF-05212384 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI In Metastatic Colorectal Cancer
This is a multicenter, open label Phase 1b/2 study in patients with metastatic colorectal carcinoma. The Phase 1b will identify the dose of the combination of PF-05212384 plus FOLFIRI.
- Trial name
- NCT01937715
- Testing
- PF-05212384, FOLFIRI regimen, Bevacizumab
- Where
- 39 sites in United States, Canada and 1 more
- Volunteers
- 18 people
- Sponsor
- Pfizer
Colorectal Cancer, Head and Neck Cancer
Pharmocokinetic/Pharmacodynamic (PK/PD) Study of the Combination Cetuximab/Gefitinib
This is an open-label, phase 1, non-randomised, non-controlled trial, carried out in two centres on patients with advanced cancer expressing EGFR.
- Conditions
- Colorectal Cancer, Head and Neck Cancer, Non Small Cell Lung Cancer (NSCLC)
- Trial name
- NCT00820417
- Testing
- Cetuximab/Gefitinib combination and/or monotherapy
- Where
- 2 sites in Belgium, Spain
- Volunteers
- 63 people
- Sponsor
- Harrison Clinical Research
Solid Tumor, Biliary Tract Cancer
Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors
This study consists of phase 1b and 2a to evaluate safety, Pharmacokinetics, and efficacy of TU2218 in combination with Pembrolizumab in patients with advanced solid tumors.
- Conditions
- Solid Tumor, Biliary Tract Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer
- Trial name
- NCT05784688
- Testing
- TU2218 + KEYTRUDA® (Pembrolizumab)
- Where
- 11 sites in United States, South Korea
- Volunteers
- 140 people
- Sponsor
- TiumBio Co., Ltd.
Colorectal Cancer
A Study of SC-006 and in Combination With ABBV-181 in Subjects With Advanced Colorectal Cancer
This is a multicenter, open-label, Phase 1 study of SC-006 given as a single agent and in combination with ABBV-181 in participants with advanced colorectal cancer (CRC), and consists of Part A (single agent SC-006 dose regimen…
- Trial name
- NCT03035279
- Testing
- SC-006, ABBV-181
- Where
- 9 sites in United States
- Volunteers
- 29 people
- Sponsor
- AbbVie
Colorectal Cancer, CRC
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors combined with Standard(s) of Care (SOC) or with novel agents.
- Conditions
- Colorectal Cancer, CRC, Pancreatic Ductal Adenocarcinoma, PDAC
- Trial name
- NCT06445062
- Testing
- RMC-6236, mFOLFOX6 regimen, bevacizumab
- Where
- 32 sites in United States
- Volunteers
- 1,130 people
- Sponsor
- Revolution Medicines, Inc.
Ovarian Cancer, Epithelial, Gastric Cancer
A Study of NX-1607 in Adults With Advanced Malignancies
This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-1607 in patients with advanced malignancies.
- Conditions
- Ovarian Cancer, Epithelial, Gastric Cancer, GastroEsophageal Junction (GEJ) Cancer, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT05107674
- Testing
- NX-1607, Paclitaxel
- Where
- 17 sites in United States, United Kingdom
- Volunteers
- 345 people
- Sponsor
- Nurix Therapeutics, Inc.
Metastatic Colorectal Cancer
CY-503 for the Treatment of Chemotherapy-refractory Metastatic Colorectal Cancer
This trial is designed as a phase II evaluation of the effect of CY-503 or placebo on progression free survival (PFS) defined as the time from start of treatment until the objective observation of progressive disease (PD) or…
- Trial name
- CY503C2 (NCT00932724)
- Testing
- CY-503
- Where
- 33 sites in Austria, Germany
- Volunteers
- 77 people
- Sponsor
- Cytavis Biopharma GmbH
Breast Cancer, Colorectal Cancer
A Study of Poziotinib in Patients With Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Activating Mutations in Advanced Malignancies
This is a Phase 2, open-label, multicenter study whose principal objectives are to evaluate the efficacy and safety/tolerability of poziotinib in five cohorts of 30 previously-treated patients each.
- Conditions
- Breast Cancer, Colorectal Cancer, Solid Tumor, Glioblastome Multiforme
- Trial name
- NCT04172597
- Testing
- Poziotinib Hydrochloride, Loperamide
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Spectrum Pharmaceuticals, Inc
Solid Tumor, Adult, Colorectal Cancer
Study of IK-595 in RAS- or RAF-altered Advanced Tumors
This is a Phase 1, FIH, Dose Escalation and Dose Expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) effects, and preliminary antitumor activity of IK-595, a MEK/RAF molecular glue…
- Conditions
- Solid Tumor, Adult, Colorectal Cancer, Pancreatic Cancer, Malignant Melanoma
- Trial name
- NCT06270082
- Testing
- IK-595
- Where
- 15 sites in United States
- Volunteers
- 75 people
- Sponsor
- Ikena Oncology
Gastric/Gastroesophageal Junction Adenocarcinoma, Metastatic Colorectal Cancer (CRC)
A Phase II Clinical Study Evaluating SSGJ-706 in Combination Therapy for Advanced Gastrointestinal Cancers
This study is a multicenter, open-label, phase II clinical trial evaluating the combination of SSGJ-706 with standard therapy for advanced gastrointestinal tumors.
- Conditions
- Gastric/Gastroesophageal Junction Adenocarcinoma, Metastatic Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Oesophageal Cancer
- Trial name
- NCT07233850
- Testing
- SSGJ-706+XELOX, SSGJ-706+Bevacizumab+XELOX, SSGJ-706+AG
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Shenyang Sunshine Pharmaceutical Co., LTD.
Melanoma (Skin), Triple-Negative Breast Cancer
START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer
This study is being conducted to explore the immunological mechanism of action of Peptide-coated Conditionally Replicating Adenovirus-1 (PeptiCRAd-1) plus Checkpoint inhibitor (CPI) therapy in multiple cancer types, as well as to…
- Conditions
- Melanoma (Skin), Triple-Negative Breast Cancer, Non-Small Cell Lung Cancer, Synovial Sarcoma
- Trial name
- NCT05492682
- Testing
- PeptiCRAd-1, Cyclophosphamide, Pembrolizumab
- Where
- 7 sites in Germany, Italy
- Volunteers
- 15 people
- Sponsor
- Valo Therapeutics Oy
Solid Tumor, NSCLC
SumMET: Study of [225Ac]Ac-FL-261 in Participants With Solid Tumors Overexpressing c-MET
This is a first-in-human, multicenter, open-label Phase 1/2 study designed to evaluate the safety, efficacy, and tolerability of [225Ac]Ac-FL-261, a targeted radioligand therapy directed at c-MET, in participants with advanced or…
- Conditions
- Solid Tumor, NSCLC, Colorectal Cancer, Head and Neck Cancer
- Trial name
- NCT07873450
- Testing
- [225Ac]Ac-FL-261
- Where
- 2 sites in United States, Australia
- Volunteers
- 208 people
- Sponsor
- Full-Life Technologies UK Limited
Metastatic Colorectal Cancer, CRC
Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation
The purpose of this study is to assess 2 different doses of onvansertib to select the lowest dose that is maximally effective, and to assess the safety, efficacy, pharmacokinetics, and pharmacodynamics of onvansertib in…
- Conditions
- Metastatic Colorectal Cancer, CRC, KRAS/NRAS Mutation
- Trial name
- NCT06106308
- Testing
- Onvansertib, FOLFIRI, Bevacizumab
- Where
- 41 sites in United States
- Volunteers
- 110 people
- Sponsor
- Cardiff Oncology
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.